4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.

导出 OA

翻译打印收藏纠错

作者： Seongseok,Yun ^[1] ; Nicole D,Vincelette ^[1] ; Katherine L B,Knorr ^[1] ; Luciana L,Almada ^[2] ; Paula A,Schneider ^[2] ; Kevin L,Peterson ^[2] ; Karen S,Flatten ^[2] ; Haiming,Dai ^[3] ; Keith W,Pratz ^[4] ; Allan D,Hess ^[4] ; B Douglas,Smith ^[4] ; Judith E,Karp ^[4] ; Andrea E Wahner,Hendrickson ^[2] ; Martin E,Fernandez-Zapico ^[5] ; Scott H,Kaufmann ^[6]

作者单位： Department of Molecular Pharmacology and Experimental Therapeutics and. ^[1] Department of Oncology, Mayo Clinic, Rochester, MN; ^[2] Department of Molecular Pharmacology and Experimental Therapeutics and Department of Oncology, Mayo Clinic, Rochester, MN; ^[3] Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, MD; and. ^[4] Department of Molecular Pharmacology and Experimental Therapeutics and Department of Oncology, Mayo Clinic, Rochester, MN; Department of Medicine and Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN. ^[5] Department of Molecular Pharmacology and Experimental Therapeutics and Department of Oncology, Mayo Clinic, Rochester, MN; Department of Medicine and. ^[6]